Key Highlights
- ETST traded around $0.09 at last closing, with a market Capitalization of roughly $26 million.
- The company announced the Acquisition of California compounding pharmacy Meduvo LLC on August 12, 2026.
- A second acquisition, veterinary-market entrant Zoolzy LLC, was announced on August 19, 2026.
- Earth Science Tech's SEC filing history shows recent 8-Ks but no periodic 10-K or 10-Q since 2022.
Earth Science Tech has quietly reinvented itself from a former consumer-wellness name into an acquisitive healthcare roll-up, and 2026 has been its busiest stretch yet. The over-the-counter stock trades for pennies, so the small percentage move flagged at last closing means little on its own. The more relevant developments are a run of acquisitions and fresh fiscal results that reshape what the company is trying to become.
Company and Latest Development
Earth Science Tech, Inc. (OTC:ETST) is a Miami, Florida-based company that describes itself as a vertically integrated healthcare platform combining compounding pharmacy operations, telemedicine, clinical support and patient fulfillment, alongside real estate holdings and consumer products. The company has been consolidating in the compounding-pharmacy space: on August 12, 2026 it announced the acquisition of California compounding pharmacy Meduvo LLC to expand its national footprint, and on August 19, 2026 it announced the acquisition of Zoolzy LLC to enter the veterinary market and drive Margin expansion.
What Is Driving Attention Around ETST?
The roughly 3.8% drift at last closing has no distinct public catalyst; at a share price under a dime, ordinary trading produces large percentage swings on minimal volume. What is genuinely driving the narrative is deal activity and reporting cadence. In addition to the two August acquisitions, Earth Science Tech reported fiscal first-quarter 2027 results (for the period ended June 30, 2026) on August 7, 2026, and fiscal year-end results for the period ended March 31, 2026 on June 18, 2026, accompanied by an annual Shareholder letter. The company operates on a March 31 fiscal year.
Key Numbers and Company Position
ETST traded around $0.09 at last closing, with a market capitalization of roughly $26 million. Beyond price and market value, investors should treat the company's financial specifics with caution. Its SEC filing history shows recent 8-K current reports but no periodic 10-K or 10-Q filings in the full-text record since 2022, suggesting it may report primarily through OTC Markets disclosures rather than full SEC periodic reporting. Any revenue, margin or cash figures tied to the acquisitions or fiscal results should be verified directly in the company's own disclosures.
What Could Come Next?
The near-term storyline centers on integration. Investors may watch whether the Meduvo and Zoolzy acquisitions close on stated terms and contribute the margin expansion management has cited, along with any further roll-up deals in compounding pharmacy, telehealth or adjacent healthcare services. Additional fiscal updates, the next shareholder communications, and any move toward more complete public reporting or an up-listing would also be relevant developments to monitor.
Risks to Watch
The risks are substantial and typical of sub-dime OTC micro-caps. Liquidity is thin, spreads are wide, and transparency is limited, particularly given the gap in periodic SEC filings. An acquisition-led strategy carries integration, execution and financing risk, and small companies often fund deals through stock or Debt that can dilute existing holders. Consumer-products and real-estate exposure add complexity to the healthcare thesis. As with any penny stock, the potential for Volatility and for permanent capital loss is elevated.
An Acquisition-Led Roll-Up Still Building Its Footprint
Earth Science Tech is pursuing an ambitious healthcare roll-up, adding a California compounding pharmacy and a veterinary-market entry in August 2026 while reporting fiscal results on a March year-end cycle. Investors may be watching whether the acquisitions close and integrate profitably, whether reporting transparency improves, and how the company funds further expansion.






Please wait processing your request...